Highlights

Cancer Pharmacogenomics: Integrating Discoveries in Basic, Clinical and Population Sciences to Advance Predictive Cancer Care

The Trans-NCI Pharmacogenomics and Pharmacoepidemiology Working Group (PPWG) and Division of Cancer Control and Population Sciences (DCCPS) sponsored the workshop “Cancer Pharmacogenomics: Integrating Discoveries in Basic, Clinical and Population Sciences to Advance Predictive Cancer Care” on October 28, 2010 in Bethesda, MD. The meeting brought together experts from various disciplines in the cancer and pharmacology research communities to discuss how a comprehensive and integrated scientific approach to cancer pharmacogenimics research can be used to accelerate discoveries in predictive cancer medicine to application. The goal of this Workshop was to examine how discoveries in basic, clinical and population sciences can build upon each other to advance the science and how this can be facilitated by multidisciplinary collaborations and partnerships.

The workshop was organized by Andrew N. Freedman, Ph.D., Chair of the PPWG, and Chief, Clinical and Translational Epidemiology Branch (CTEB) in the Epidemiology and Genetics Research Program (EGRP), DCCPS, and Leah B. Sansbury, Ph.D., M.S.P.H., Co-Chair of PPWG’s Population Sciences Sub-Group, and Program Director, CTEB.

AGENDA
Thursday, October 28, 2010
7:30 a.m. - 5:30 p.m.
Pooks Hill Marriott
Bethesda, MD

Pathways to Pharmacogenomic Discovery
7:30 a.m. – 8:00 a.m. Registration and Continental Breakfast
8:00 a.m. – 8:20 a.m. Welcome and Introduction

Jeffrey S. Abrams, M.D.
Associate Director, Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute (NCI)
National Institutes of Health (NIH)
8:20 a.m. – 8:45 a.m. Workshop Overview and Objectives

Andrew N. Freedman, Ph.D.
Branch Chief, Clinical and Translational Epidemiology Branch
Division of Cancer Control and Population Sciences (DCCPS)
NCI, NIH
Session I: What can we learn from Randomized Clinical Trials?
Moderator: William D. Figg, M.D.
8:45 a.m. – 9:10 a.m. James N. Ingle, M.D.
Mayo Clinic

Using retrospective analysis of RCTs to discover germline pharmacogenomic (PGx) markers of treatment toxicity: The example of a genome-wide association (GWAS) study in patients experiencing musculoskeletal adverse events on aromatase inhibitors as adjuvant therapy in early breast cancer entered on NCIC CTG Trial MA.27
9:10 a.m. – 9:35 a.m. Daniel F. Hayes, M.D.
University of Michigan

Using retrospective analysis of RCTs to discover and validate somatic PGx markers of treatment response
9:35 a.m. – 10:00 a.m. Mary V. Relling, M.D.
St. Jude Children's Research Hospital

Using retrospective analysis of RCTs to discover and validate germline PGx markers of treatment response: The example of a GWAS of germline variation associated with treatment response in childhood acute lymphoblastic leukemia
10:00 a.m. – 10:15 a.m. Break
Moderator: Lori Minasian, M.D.
10:15 a.m. – 10:35 a.m. Roy Herbst, M.D.
M.D. Anderson Cancer Center

Conducting genome-guided prospective RCTs to identify and validate PGx markers of treatment response: The example of the BATTLE lung cancer trial
10:35 a.m. – 10:45 a.m. Richard Schilsky, M.D.
University of Chicago

IOM Cancer Clinical Trials Report and Implications for Pharmacogenomic Research
10:45 a.m. – 11:10 a.m. Panel Discussion

Moderator: Richard L. Schilsky, M.D.

Panelists:
Mary V. Relling, Ph.D., St. Jude
Howard McLeod, PhD, University of North Carolina
Mark Ratain, M.D., University of Chicago
David Flockhart, M.D., Ph.D., University of Indiana
Session II: What can we learn from observational and population-based studies?
Moderator: Leah Sansbury, Ph.D.
11:10 a.m. – 11:35 p.m.

Bruce Carleton, Ph.D.
University of British Columbia

The Canadian Pharmacogenomic Network for Drug Safety: The example of genetic variants in TPMT and COMT and their association with hearing loss in children receiving cisplatin chemotherapy
Session III: What can we learn from cell based models and functional studies?
11:35 a.m. – 12:00 p.m. Dr. Eileen Dolan, Ph.D.
University of Chicago

Pharmacogenomic Discovery Using Cell-Based Models
12:00 p.m. – 1:00 p.m. Lunch
Session IV: What can we learn from incorporating pharmacogenomics in early drug development?
Moderator: William D. Figg, M.D.
1:00 p.m. – 1:25 p.m.

Timothy Yap, M.D.
Cancer Research UK Centre for Cancer Therapeutics

Envisioning the future of early anticancer drug development
Session V: Recommendations for the future of pharmacogenomic research
8-10 minute talks for each speaker
Moderator: Andrew Freedman, Ph.D.
1:25 p.m. – 2:45 p.m. Speakers:
Felix Frueh M.D.
Medco

Patricia Deverka, Ph.D.
Center for Medical Technology and Policy

Geoff Liu, M.D.
Princess Margaret Hospital, University of Toronto

Christine Ambrosone, Ph.D.
Roswell Park Cancer Institute

Richard M. Weinshilboum, M.D.
Mayo Clinic

Samir Khleif, M.D.
NCI
2:45 p.m. – 3:00 p.m. Leah Sansbury, Ph.D.
Charge to Priority Setting Sessions
3:00 p.m. – 3:15 p.m. Break
Session VI: Priority Setting Sessions (4 concurrent discussion sessions)
3:15 p.m. – 4:30 p.m. Priority Setting Session A: Basic Science and Drug Discovery
  • Leaders: Lie Wei Wang, Ph.D.
  • Facilitator: William D. Figg, M.D.

Priority Setting Session B: Clinical Science

  • Leaders: James Ingle, M.D. and Daniel Hayes, M.D.
  • Facilitator: Rochelle Long, Ph.D.

Priority Setting Session C: Observational Science

  • Leaders: Cornelia Ulrich, Ph.D. and Lois Travis Ph.D.
  • Facilitator: Leah Sansbury, Ph.D.

Priority Setting Session D: Translation, Knowledge Synthesis and Implementation

  • Leaders: Mary Relling, Ph.D. and Felix Frueh M.D.
  • Facilitator: Sheri Schully, Ph.D.
Session VII: Report from Priority Setting Sessions
Moderator: Lori Minasian, M.D.
4:30 p.m. – 5:30 p.m. Session Leaders

Last Updated: 11 Jun 2012

Division of Cancer Control and Population Sciences National Cancer Institute Department of Health and Human Services National Institutes of Health USA.gov